資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32502
|
| 標題: | Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study |
| 作者: | Hung, Peir-Haur
Yeh, Chih-Ching
Sung, Fung-Chang
Hsiao, Chih-Yen
Muo, Chih-Hsin
Hung, Kuan-Yu
Tsai, Kuen-Jer |
| 貢獻者: | Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med
Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth
Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth
China Med Univ, Dept Publ Hlth
China Med Univ Hosp, Management Off Hlth Data
China Med Univ, Coll Med, Sch Med, Grad Inst Clin Med Sci
Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Internal Med
Natl Cheng Kung Univ, Coll Med, Inst Clin Med
Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Ctr Clin Med |
| 關鍵字: | Alzheimer's disease
erythropoietin
end-stage renal disease
hemodialysis |
| 日期: | 2019 |
| 上傳時間: | 2020-07-29 13:47:36 (UTC+8) |
| 出版者: | IMPACT JOURNALS LLC |
| 摘要: | Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron. |
| 關聯: | Aging-Us, v.11, n.17, pp. |
| 顯示於類別: | [生活保健科技系] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1159 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
